A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Variant-containing Formulations
Phase 4
832
about 10 months
12+
5 sites in GA, LA, MS +1
About this study
This trial is testing a new type of COVID-19 vaccine called mNEXSPIKE® that contains a variant of the virus. The goal is to see how well it creates an immune response (immunogenicity) and whether it's safe for people, including adults and children.
Based on ClinicalTrials.gov records.
What participants do
- 1.Receive mRNA-1283.251 Variant-containing Formulation
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Secondary: Subprotocol 1: Part A - Number of Participants with Unsolicited Adverse Events (AEs), Serious Adverse Events (SAEs), AEs of Special Interests (AESIs), and AEs Leading to Study Withdrawal, Subprotocol 1: Part B - Number of Participants with SAEs, AESIs, and AEs Leading to Study Withdrawal, Subprotocol 1: Part B - Number of Participants with Unsolicited AEs
Infectious